Researchers track Long-Term effects of romiplostim in rare blood disorder

NCT ID NCT04870346

Ongoing Knowledge-focused Sponsor: Kyowa Kirin Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study follows 36 patients with aplastic anemia who previously received romiplostim in earlier trials. Researchers will monitor blood cell counts and safety for up to 5 years to see if benefits last and to check for any new health issues. The goal is to better understand the long-term effects of this treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: romiplostim
What this could lead to: If successful, this could confirm whether romiplostim provides lasting benefits for aplastic anemia patients without ongoing treatment.
What could go wrong: This is an observational follow-up, not a new treatment trial. It may not show clear long-term benefits, and results depend on a small group of patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aplastic anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APLASTIC ANEMIA

Contacts and locations

Locations

Kanazawa University, College of Medical Pharmaceutical and Health Sciences, School of Medicine, Department of Hematology

Kanazawa, Ishikawa-ken, 920-0934, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.